Search

Your search keyword '"Horowitz, Netanel A."' showing total 41 results
Start Over Author "Horowitz, Netanel A." Publication Year Range Last 3 years
41 results on '"Horowitz, Netanel A."'

2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

7. Flow-cytometry Assessment of DNA content Analysis and Immunophenotyping of Immune-cells in Lymph-node-specimens as Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas

Author

Azoulay, David, primary, Tapuchi, Tal, additional, Ronen, Ohad, additional, Akria, Luiza, additional, Cohen, Hector I, additional, Surio, Celia, additional, Rodin Chepa, Svetlana, additional, Zarfati, Moran, additional, Stemmer, Galia, additional, Eshel, Elizabeth, additional, and Horowitz, Netanel A, additional

Published
2024
Full Text
View/download PDF

8. 2654. International Multi-Center Study Comparing the Effect of Obinutuzumab or Rituximab Treatment in Hematological Patients on COVID-19 Outcomes During the Omicron Surge

Author

Shafat, Tal, primary, Grupel, Daniel, additional, Porges, Tzvika, additional, Belkin, Ana, additional, Deri, Ofir, additional, Oster, Yonatan, additional, Zahran, Shadi, additional, Horwitz, Ehud, additional, Horowitz, Netanel A, additional, Khatib, Hazim, additional, Batista, Marjorie, additional, Cortez, Anita, additional, Brosh-Nissimov, Tal, additional, Segman, Yafit, additional, Ishay, Linor, additional, Cohen, Regev, additional, Atamna, Alaa, additional, Spallone, Amy, additional, Chemaly, Roy F, additional, Ramos, Juan Carlos, additional, Chowers, Michal, additional, Rogozin, Evgeny, additional, Carmi-Oren, Noga, additional, Keske, Şiran, additional, Barchad, Orit Wolfovitz, additional, and Nesher, Lior, additional

Published
2023
Full Text
View/download PDF

10. Flow-cytometry Assessment of DNA content Analysis and Immunophenotyping of Immune-cells in Lymph-node-specimens as Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas

Author

Tapuchi, Tal, primary, Ronen, Ohad, additional, Akria, Luiza, additional, Cohen, Hector I, additional, Surio, Celia, additional, Rodin Chepa, Svetlana, additional, Zarfati, Moran, additional, Stemmer, Galia, additional, Horowitz, Netanel A, additional, and Azoulay, David, additional

Published
2023
Full Text
View/download PDF

11. An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.

Author

Shafat, Tali, Grupel, Daniel, Porges, Tzvika, Abuhasira, Ran, Belkin, Ana, Deri, Ofir, Oster, Yonatan, Zahran, Shadi, Horwitz, Ehud, Horowitz, Netanel A., Khatib, Hazim, Batista, Marjorie Vieira, Cortez, Anita Cassoli, Brosh‐Nissimov, Tal, Segman, Yafit, Ishay, Linor, Cohen, Regev, Atamna, Alaa, Spallone, Amy, and Chemaly, Roy F.

Subjects
HEMATOLOGIC malignancies, SARS-CoV-2 Omicron variant, RITUXIMAB, COVID-19, MONOCLONAL antibodies
Abstract

Objectives: Hematological malignancy (HM) patients treated with anti‐CD20 monoclonal antibodies are at higher risk for severe COVID‐19. A previous single‐center study showed worse outcomes in patients treated with obinutuzumab compared to rituximab. We examined this hypothesis in a large international multicenter cohort. Methods: We included HM patients from 15 centers, from five countries treated with anti‐CD20, comparing those treated with obinutuzumab (O‐G) to rituximab (R‐G) between December 2021 and June 2022, when Omicron lineage was dominant. Results: We collected data on 1048 patients. Within the R‐G (n = 762, 73%), 191 (25%) contracted COVID‐19 compared to 103 (36%) in the O‐G. COVID‐19 patients in the O‐G were younger (61 ± 11.7 vs. 64 ± 14.5, p = 0.039), had more indolent HM diagnosis (aggressive lymphoma: 3.9% vs. 67.0%, p < 0.001), and most were on maintenance therapy at COVID‐19 diagnosis (63.0% vs. 16.8%, p < 0.001). Severe‐critical COVID‐19 occurred in 31.1% of patients in the O‐G and 22.5% in the R‐G. In multivariable analysis, O‐G had a 2.08‐fold increased risk for severe‐critical COVID‐19 compared to R‐G (95% CI 1.13–3.84), adjusted for Charlson comorbidity index, sex, and tixagevimab/cilgavimab (T‐C) prophylaxis. Further analysis comparing O‐G to R‐G demonstrated increased hospitalizations (51.5% vs. 35.6% p = 0.008), ICU admissions (12.6% vs. 5.8%, p = 0.042), but the nonsignificant difference in COVID‐19‐related mortality (n = 10, 9.7% vs. n = 12, 6.3%, p = 0.293). Conclusions: Despite younger age and a more indolent HM diagnosis, patients receiving obinutuzumab had more severe COVID‐19 outcomes than those receiving rituximab. Our findings underscore the need to evaluate the risk–benefit balance when considering obinutuzumab therapy for HM patients during respiratory viral outbreaks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma

Author

Bairey, Osnat, primary, Taliansky, Alisa, additional, Glik, Amir, additional, Amiel, Alexandra, additional, Yust‐Katz, Shlomit, additional, Gurion, Ronit, additional, Zektser, Miri, additional, Porges, Tzvika, additional, Sarid, Nadav, additional, Horowitz, Netanel A., additional, Shina, Tzahala Tzuk, additional, Lebel, Eyal, additional, Cohen, Amos, additional, Geiger, Karyn Revital, additional, Raanani, Pia, additional, Wolach, Ofir, additional, and Siegal, Tali, additional

Published
2023
Full Text
View/download PDF

13. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

Author

Vainstein, Vladimir, primary, Avni, Batia, additional, Grisariu, Sigal, additional, Kfir-Erenfeld, Shlomit, additional, Asherie, Nathalie, additional, Nachmias, Boaz, additional, Auman, Shlomtzion, additional, Saban, Revital, additional, Zimran, Eran, additional, Assayag, Miri, additional, Filanovsky, Kalman, additional, Horowitz, Netanel A., additional, Lebel, Eyal, additional, Shaulov, Adir, additional, Gur, Michal, additional, Rosenbluh, Chaggai, additional, Krichevsky, Svetlana, additional, Stepensky, Polina, additional, and Gatt, Moshe E., additional

Published
2023
Full Text
View/download PDF

18. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era

Author

Vassilakopoulos, Theodoros P., primary, Panitsas, Fotios, additional, Mellios, Zois, additional, Apostolidis, John, additional, Michael, Michalis, additional, Gurion, Ronit, additional, Ferhanoglu, Burhan, additional, Hatzimichael, Eleftheria, additional, Karakatsanis, Stamatios, additional, Dimou, Maria, additional, Kalpadakis, Christina, additional, Katodritou, Eirini, additional, Leonidopoulou, Theoni, additional, Kotsianidis, Ioannis, additional, Giatra, Hara, additional, Kanellias, Nick, additional, Sayyed, Ayman, additional, Tadmor, Tamar, additional, Akay, Olga Meltem, additional, Angelopoulou, Maria K., additional, Horowitz, Netanel, additional, Bakiri, Maria, additional, Pangalis, Gerassimos A., additional, Panayiotidis, Panayiotis, additional, and Papageorgiou, Sotirios G., additional

Published
2022
Full Text
View/download PDF

19. Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Author

Harlev, Shimrit, primary, Fadaos, Nashwa, additional, Azoulay, Tehila, additional, Leiba, Ronit, additional, Horesh, Nurit, additional, Inbar, Tsofia, additional, Horowitz, Netanel A., additional, Tsoran-Rosenthal, Inna, additional, Lavi, Noa, additional, Dann, Eldad J., additional, and Zuckerman, Tsila, additional

Published
2022
Full Text
View/download PDF

20. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Author

Vassilakopoulos, Theodoros P., primary, Panitsas, Fotios, additional, Mellios, Zois, additional, Apostolidis, John, additional, Piperidou, Alexia, additional, Michael, Michalis D, additional, Gurion, Ronit, additional, Akay, Meltem, additional, Hatzimichael, Eleftheria, additional, Karakatsanis, Stamatis J., additional, Dimou, Maria, additional, Kalpadakis, Christina, additional, Katodritou, Eirini, additional, Leonidopoulou, Theoni, additional, Kotsianidis, Ioannis, additional, Giatra, Chara, additional, Kanellias, Nikolaos, additional, Sayyed, Ayman, additional, Tadmor, Tamar, additional, Kaynar, Leylagul, additional, Zektser, Miri, additional, Symeonidis, Argiris, additional, Atalar, SC, additional, Verrou, Evgenia, additional, Gutwein, Odit, additional, Ganzel, Chezi, additional, Karianakis, Giorgos, additional, Isenberg, Jonathan, additional, Gainaru, Gabriela, additional, Triantafyllou, Theodora, additional, Vrakidou, Efimia, additional, Palassopoulou, Maria, additional, Ozgur, Mehmet, additional, Paydas, Semra, additional, Tsirigotis, Panagiotis, additional, Tsirogianni, Maria, additional, Tuglular, Tulin, additional, Chatzidimitriou, Chrysovalantou, additional, Kotsopoulou, Maria, additional, Terpos, Evangelos, additional, Zikos, Panagiotis, additional, Koumarianou, Argyro, additional, Poziopoulos, Christos, additional, Boutsis, Dimitrios, additional, Gafter-Gvili, Anat, additional, Karmiris, Themistoklis, additional, Angelopoulou, Maria K., additional, Bakiri Papaioannou, Maria, additional, Pangalis, Gerassimos, additional, Panayiotidis, Panayiotis, additional, Ferhanoglu, Burhan, additional, Horowitz, Netanel A., additional, and Papageorgiou, Sotirios, additional

Published
2022
Full Text
View/download PDF

21. Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Olszewski, Adam J., primary, Avigdor, Abraham, additional, Babu, Sunil, additional, Levi, Itai, additional, Eradat, Herbert, additional, Abadi, Uri, additional, Holmes, Houston, additional, McKinney, Matthew, additional, Woszczyk, Dariusz, additional, Giannopoulos, Krzysztof, additional, Jurczak, Wojciech, additional, Dunshee, Diana, additional, Yang, Annie, additional, Zhou, Mingzhu, additional, Qayum, Naseer, additional, Sellam, Gila, additional, and Horowitz, Netanel A., additional

Published
2022
Full Text
View/download PDF

22. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study

Author

Shargian, Liat, primary, Amit, Odelia, additional, Bernstine, Hanna, additional, Gurion, Ronit, additional, Gafter‐Gvili, Anat, additional, Rozovski, Uri, additional, Pasvolsky, Oren, additional, Perets, Galit, additional, Horowitz, Netanel A., additional, Halloun, Jabour, additional, Perry, Chava, additional, Avivi, Irit, additional, Raanani, Pia, additional, Yeshurun, Moshe, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

23. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group

Author

Ganzel, Chezi, primary, Trestman, Svetlana, additional, Levi, Shai, additional, Gatt, Moshe E., additional, Lavi, Noa, additional, Vaxman, Iuliana, additional, Rouvio, Ory, additional, Magen, Hila, additional, Lebel, Eyal, additional, Horowitz, Netanel A., additional, Leiba, Merav, additional, Tadmor, Tamar, additional, Herzog Tzarfati, Katrin, additional, Surio, Celia, additional, Yeganeh, Shay, additional, Dally, Nagib, additional, Avivi, Irit, additional, and Cohen, Yael C., additional

Published
2022
Full Text
View/download PDF

24. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study

Author

Shragai, Tamir, primary, Magen, Hila, additional, Lavi, Noa, additional, Gatt, Moshe, additional, Trestman, Svetlana, additional, Zektser, Miri, additional, Ganzel, Chezi, additional, Jarchowsky, Osant, additional, Berger, Tamar, additional, Tadmor, Tamar, additional, Leiba, Merav, additional, Hertzog-Zarfaty, Katrin, additional, Horowitz, Netanel, additional, Shapira, Michael, additional, Varssano, David, additional, Berger, Yoav, additional, Frenkel, Shahar, additional, Krauthammer, Mark, additional, Avivi, Irit, additional, Luttwak, Efrat, additional, and Cohen, Yael, additional

Published
2022
Full Text
View/download PDF

25. Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review.

Author

Krayem, Baher, Brenner, Benjamin, and Horowitz, Netanel A.

Subjects
HEMATOLOGIC malignancies, PREGNANT women, FETAL growth retardation, DATABASE management, THROMBOSIS, THROMBOTIC thrombocytopenic purpura, MYELOFIBROSIS
Abstract

Cancer and pregnancy induce a procoagulant environment which may lead to maternal and fetal complications, such as venous thromboembolism, fetal growth restriction, and fetal loss. The incidence of hematological malignancies diagnosed during pregnancy is rising, and thrombotic events in such malignancies are not rare. Management of thrombosis during pregnancy poses a therapeutic challenge, that is further exacerbated by the impact of cancer. The available data on managing pregnant women with hematological malignancies are limited to those with myeloproliferative neoplasms, mainly essential thrombocythemia, and, to a lesser extent, polycythemia vera. Low-dose aspirin is recommended throughout pregnancy, and considering treatment with low-molecular-weight heparin and interferon formulations is advised for high-risk patients. Currently, guidelines for handling thrombotic events in pregnant women with lymphoma or leukemia are lacking, and their management is based on data extrapolated from retrospective studies, and guidelines for prevention and treatment of cancer-associated thrombosis. The present case-based review will focus on the complex issue of thrombotic risk in pregnant women with hematological malignancies, specifically myeloproliferative neoplasms, lymphomas, and leukemias. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression.

Author

Ringelstein‐Harlev, Shimrit, Fanadka, Mona, Horowitz, Netanel A., Bettman, Noam P., and Katz, Tami

Subjects
CHRONIC lymphocytic leukemia, THROMBOPOIETIN receptors, IDIOPATHIC thrombocytopenic purpura, T cells, IMMUNOSUPPRESSION
Abstract

In chronic lymphocytic leukemia (CLL), the immune system is skewed towards a suppressive milieu. Levels of thrombopoietin (TPO), promoting cellular immune regulatory activity in immune thrombocytopenic purpura, were shown to be elevated in CLL patients. This study explored TPO as a potential immunomodulator, supporting CLL progression. We evaluated CLL cell‐induced expression of TPO receptor (TPO‐R) on T‐cells and effects of its activation on T‐cell responses. CLL cell involvement in TPO generation was also assessed. Baseline TPO‐R expression on CD4 + T‐cells was found to be higher in CLL patients than in healthy controls (HC). Exposure of HC‐T‐cells to B‐cells, especially to CLL‐B‐cells stimulated with B‐cell activating molecules, resulted in enhanced TPO‐R expression on T‐cells. CLL‐T‐cell stimulation with TPO reduced their proliferation and expanded the regulatory T‐cell (Treg) population. At baseline, phosphorylation of STAT5, known to impact the Treg phenotype, was elevated in CLL‐T‐cells relative to those of HC. Exposure to TPO further enhanced STAT5 phosphorylation in CLL‐T‐cells, possibly driving the observed Treg expansion. The CLL immune milieu is involved in promotion of inhibitory features in T‐cells through increased TPO‐R levels and TPO‐induced intracellular signaling. TPO and its signaling pathway could potentially support immunosuppression in CLL, and may emerge as novel therapeutic targets. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Revisiting SARS-CoV-2 environmental contamination by patients with COVID-19: The Omicron variant does not differ from previous strains

Author

Glinert, Itai, primary, Ben-Shmuel, Amir, additional, Szwartcwort-Cohen, Moran, additional, Beth-din, Adi, additional, Laskar, Orly, additional, Barlev-Gross, Moria, additional, Melamed, Sharon, additional, Arbell, Noga, additional, Levy, Haim, additional, Horowitz, Netanel A, additional, and Weiss, Shay, additional

Published
2022
Full Text
View/download PDF

28. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.

Author

Shargian, Liat, Amit, Odelia, Bernstine, Hanna, Gurion, Ronit, Gafter‐Gvili, Anat, Rozovski, Uri, Pasvolsky, Oren, Perets, Galit, Horowitz, Netanel A., Halloun, Jabour, Perry, Chava, Avivi, Irit, Raanani, Pia, Yeshurun, Moshe, and Ram, Ron

Subjects
DISEASE relapse, DIFFUSE large B-cell lymphomas, STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, SALVAGE therapy, PROGRESSION-free survival
Abstract

Objectives: To evaluate the role of additional chemotherapy before autologous hematopoietic cell transplantation (HCT) in patients with relapse/refractory diffuse large B‐cell lymphoma (DLBCL) who achieve partial remission following first salvage therapy. Methods: We conducted a multicenter retrospective study of all adult patients with DLBCL who underwent HCT between 2008 and 2020 and achieved partial response (PR) after the first salvage and were either referred directly to HCT (n = 47) or received additional salvage therapy before HCT (n = 22). Results: Post‐HCT CR rate and progression‐free survival were comparable between the two groups (66% vs. 68%, p =.86 and median not reached vs. 10.2 months [95% confidence interval, CI 7.1–12.3], p =.27, respectively). Median overall survival (OS) and estimated 3‐year OS favored patients who were directly referred to HCT (105.8 [95% CI 63–148] months vs. 14.5 [95% CI 0–44] months, p =.035, and 65% [95% CI 51%–75%] vs. 40% [95% CI 21%–53%], p =.035, respectively). In Cox regression model, while International Prognostic Index and primary refractory versus relapse disease did not impact OS, allocation to a second salvage regimen and older age were both associated with inferior survival (hazard ratio [HR] = 2.57 95% CI 1.1–5.8, p =.023 and HR = 1.04 95% CI 0.99–1.2, p =.064, respectively). Conclusions: Referring patients with chemotherapy‐sensitive disease in PR directly to HCT is associated with better OS compared to those receiving additional lines of treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.

Author

Shragai, Tamir, Magen, Hila, Lavi, Noa, Gatt, Moshe, Trestman, Svetlana, Zektser, Miri, Ganzel, Chezi, Jarchowsky, Osnat, Berger, Tamar, Tadmor, Tamar, Leiba, Merav, Hertzog‐Tzarfaty, Katrin, Horowitz, Netanel, Shapira, Michael, Varssano, David, Berger, Yoav, Frenkel, Shahar, Krauthammer, Mark, Avivi, Irit, and Luttwak, Efrat

Subjects
MULTIPLE myeloma, OCULAR toxicology, PROGRESSION-free survival, RETROSPECTIVE studies, OVERALL survival
Abstract

Summary: Belantamab mafodotin, an immuno‐conjugate targeting B‐cell maturation antigen, showed single‐agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real‐world data and long‐term follow‐up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One‐hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow‐up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression‐free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real‐world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

Author

Collins, Graham P., primary, Eyre, Toby A., additional, Schmitz-Rohmer, Debora, additional, Townsend, William, additional, Popat, Rakesh, additional, Giulino-Roth, Lisa, additional, Fields, Paul A., additional, Krasniqi, Fatime, additional, Soussain, Carole, additional, Stathis, Anastasios, additional, Andjelkovic, Nebojsa, additional, Cunningham, David, additional, Mandic, Danijela, additional, Radulovic, Sinisa, additional, Tijanic, Ivan, additional, Horowitz, Netanel A., additional, Kurtovic, Sabira, additional, Schorb, Elisabeth, additional, Schmidt, Christian, additional, Dimitrijević, Saša, additional, and Dreyling, Martin, additional

Published
2021
Full Text
View/download PDF

36. Continuous Remote Patient Monitoring Shows Early Cardiovascular Changes in COVID-19 Patients

Author

Eisenkraft, Arik, primary, Maor, Yasmin, additional, Constantini, Keren, additional, Goldstein, Nir, additional, Nachman, Dean, additional, Levy, Ran, additional, Halberthal, Michael, additional, Horowitz, Netanel A., additional, Golan, Ron, additional, Rosenberg, Elli, additional, Lavon, Eitan, additional, Cohen, Ornit, additional, Shapira, Guy, additional, Shomron, Noam, additional, Ishay, Arik Ben, additional, Sand, Efrat, additional, Merin, Roei, additional, Fons, Meir, additional, Littman, Romi, additional, and Gepner, Yftach, additional

Published
2021
Full Text
View/download PDF

37. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Author

Olszewski, Adam, primary, Avigdor, Abraham, additional, Babu, Sunil, additional, Levi, Itai, additional, Eradat, Herbert, additional, Abadi, Uri, additional, Holmes, Houston, additional, McKinney, Matthew, additional, Woszczyk, Dariusz, additional, Giannopoulos, Krzysztof, additional, Jurczak, Wojciech, additional, McCord, Ron, additional, Xie, Yuying, additional, Zhou, Mingzhu, additional, Qayum, Naseer, additional, O’Hear, Carol, additional, Sellam, Gila, additional, and Horowitz, Netanel, additional

Published
2021
Full Text
View/download PDF

38. Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Author

Olszewski, Adam, primary, Avigdor, Abraham, additional, Babu, Sunil, additional, Levi, Itai, additional, Eradat, Herbert, additional, Abadi, Uri, additional, Holmes, Houston, additional, McKinney, Matthew, additional, Woszczyk, Dariusz, additional, Giannopoulos, Krzysztof, additional, Jurczak, Wojciech, additional, McCord, Ron, additional, Xie, Yuying, additional, Zhou, Mingzhu, additional, Qayum, Naseer, additional, O’Hear, Carol, additional, Sellam, Gila, additional, and Horowitz, Netanel, additional

Published
2021
Full Text
View/download PDF

39. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Olszewski, Adam J, Eradat, Herbert, Avigdor, Abraham, Horowitz, Netanel A., Babu, Sunil, Levi, Itai, McKinney, Matthew, Lee, Seung Tae, Bergua Burgues, Juan Miguel, Rodriguez Izquierdo, Antonia, Bastos-Oreiro, Mariana, Ganzel, Chezi, Kim, Tae Min, Jeon, Youngwoo, Taszner, Michal, Narkhede, Mayur, Kim, Won Seog, Shin, Ho-Jin, Lavie, David, Woszczyk, Dariusz, Dunshee, Diana, Kapp, Amy V., Zhou, Mingzhu, Batlevi, Connie Lee, Ead, Wahib, Sellam, Gila, and Jurczak, Wojciech

Abstract

Background:Treatment options for elderly unfit/frail (U/F) patients (pts) with diffuse large B-cell lymphoma (DLBCL) are often limited due to comorbidities or functional decline. Less toxic, efficacious alternatives to full-dose chemoimmunotherapy (CIT) are needed. Mosunetuzumab (Mosun) is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate B cells. Mosun monotherapy has demonstrated efficacy, durable complete responses (CR), and manageable safety in U/F pts with untreated DLBCL (NCT03677154; Olszewski et al. ASH 2022). Subgroup analysis from an ongoing Phase Ib/II study (NCT03671018) of Mosun plus polatuzumab vedotin (Pola; M-Pola) in pts with relapsed/refractory DLBCL demonstrated efficacy and a manageable safety profile in pts ≥65 years (yrs) (Olszewski et al. ASH 2022). We report preliminary efficacy and safety data from the M-Pola cohort of study NCT03677154 in elderly U/F pts with newly diagnosed DLBCL.

Published
2023
Full Text
View/download PDF

40. Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Author

Gurion, Ronit, Guz, Dmitri, Kedmi, Meirav, Perry, Chava, Avivi Mazza, Irit, Horowitz, Netanel A., Abadi, Uri, Gafter-Gvili, Anat, Raanani, Pia, Goldschmidt, Neta, Nachmias, Boaz, and Aumann, Shlomzion

Abstract

Introduction- Glofitamab is a CD20-directed CD3 T-cell engager that has recently been approved by the FDA for relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL). The approval was based on a pivotal phase II study including 154 patients with a median of 3 lines of treatment (a third post chimeric antigen receptor T (CAR-T) cell therapy) demonstrating an overall response rate (ORR) and complete response (CR) rate of 52% and 39%, respectively 1. However real-life data is still lacking. The present study was aimed to determine the efficacy and safety of glofitamab in real-life settings.

Published
2023
Full Text
View/download PDF

41. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.

Author

Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P, Ben-Zvi H, Szwarcwort M, Taylor-Abigadol M, Dann EJ, Horesh N, Inbar T, Tzoran I, Lavi N, Fineman R, Ringelstein-Harlev S, and Horowitz NA

Subjects
Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, Cross-Sectional Studies, Humans, SARS-CoV-2, Vaccination, COVID-19 prevention & control, Lymphoma drug therapy, Vaccines
Abstract

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies, suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors influencing the response. Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott ) assay in blood samples drawn from lymphoma patients 4 2 weeks after the second dose of vaccine. The cutoff for a positive response was set at 50 AU/mL. Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of <12 months between the last anti-CD20 monoclonal antibody dose and the second vaccine dose (odds ratio=31.3 [95% confidence interval: 8.4-116.9], P<0.001) and presence of active lymphoma (odds ratio=4.2 (95% confidence interval: 2.1- 8.2), P=0.006) were identified as negative response predictors. The rate of seropositivity increased from 3% in patients vaccinated within 45 days after the last monoclonal antibody administration to 80% in patients vaccinated >1 year after this therapy. The latter percentage was equal to that of patients never exposed to monoclonal antibodies. In conclusion, lymphoma patients, especially those recently treated with anti- CD20 monoclonal antibodies, fail to develop sufficient humoral response to BNT162b2 vaccine. While a serological response is not the only predictor of immunity, its low level could make this population more vulnerable to COVID-19, which implies the need for a different vaccination schedule for such patients.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results